Every 8-K that Revelation Biosciences, Inc. Warrant (REVBW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow REVBW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REVBW filings page.
Revelation Biosciences, Inc. (REVB) disclosed that its Compensation Committee approved new Restricted Stock Awards for senior executives under the Amended and Restated 2021 Equity Incentive Plan, effective August 17, 2026. Chief Executive Officer James Rolke received 208,076 restricted shares and Chief Financial Officer Chester S. Zygmont, III received 208,073 restricted shares.
The awards vest in four equal 25% tranches based on the earlier of market capitalization milestones of $30 million, $60 million, $90 million, and $120 million sustained for twenty consecutive trading days, or time-based anniversaries at two and four years from grant. The awards fully vest immediately before a Change in Control, or upon certain terminations (death, termination without Cause, or resignation for Good Reason), and are otherwise forfeited if service ends under other circumstances. The form of Restricted Stock Award Agreement is filed as an exhibit.
Revelation Biosciences, Inc. reported financial results for the three and six months ended June 30, 2026 and highlighted progress on its Gemini programs. Net loss was $3,323,384, or $(0.87) per share, for the quarter and $6,332,435, or $(3.41) per share, for the six-month period.
Cash and cash equivalents were $11,482,792 as of June 30, 2026, compared with $10,700,331 at December 31, 2025, and the company expects this to fund operations through the first quarter of 2027. Total stockholders’ equity was $10,066,986, with 3,908,420 common shares outstanding. Operationally, Revelation advanced start-up activities for a Phase 2/3 acute kidney injury study of Gemini, formed and expanded an Acute Kidney Injury Advisory Board, and cited an independent assessment indicating a potential $94 billion total addressable market for Gemini.
Revelation Biosciences, Inc. adopted a stockholder rights plan via a Rights Agreement with Continental Stock Transfer & Trust Co. and declared a dividend of one preferred share purchase right for each outstanding common share to holders of record on July 21, 2026.
Each right, once exercisable, permits purchase of one one-thousandth of a share of Series B Junior Participating Preferred Stock at $20.00. The plan is triggered if a person or group acquires beneficial ownership of 10% or more of common stock (or 15% for qualifying passive investors) without prior Board approval, activating flip-in and potential flip-over protections against coercive control attempts. Before a trigger, the Board may redeem the rights for $0.001 per right. The rights expire on the first anniversary of the Rights Agreement or on the third anniversary if stockholders ratify it, subject to earlier redemption or exchange.
Revelation Biosciences, Inc. updated its leadership contracts, tightened governance rules, and obtained key shareholder approvals. The company signed amended three-year employment agreements with its CEO and CFO, increasing change-in-control severance to 2x salary plus target bonus and up to 18 months of COBRA premium reimbursement.
The board adopted amended bylaws adding detailed “Cause” definitions, universal proxy and advance-notice requirements for director nominations, and a formal emergency succession plan for the CEO and CFO. Stockholders elected one Class A director and authorized the board to carry out one or more reverse stock splits within a one-for-two to one-for-250 range, and ratified Baker Tilly US, LLP as auditor for 2026.
Revelation Biosciences, Inc. furnished an updated corporate presentation, dated June 1, 2026, and made it available to the public on its website. The presentation is attached as Exhibit 99.1 to this report under Item 8.01 Other Information and is incorporated by reference.
The company clarifies that the materials in Item 8.01 and Exhibit 99.1 are being furnished, not filed, so they are not subject to certain Exchange Act liabilities and are only incorporated into other filings if specifically referenced. Item 9.01 lists Exhibit 99.1 and an Inline XBRL cover page file as Exhibit 104.
Revelation Biosciences, Inc. reported financial results for the three months ended March 31, 2026. The company recorded a net loss of $3.0 million, or $2.71 per basic and diluted share, and net loss attributable to common stockholders of $8.7 million after $5.7 million in deemed dividends.
Cash and cash equivalents were $14.1 million as of March 31, 2026, up from $10.7 million at year-end 2025, helped by $6.7 million in net proceeds from a January 2026 warrant inducement. Management believes this cash is sufficient to fund operations through the first quarter of 2027.
Operating expenses rose as the company advanced its Gemini programs, with research and development expense of $1.4 million and general and administrative expense of $1.7 million. Revelation also highlighted agreement with the FDA on a single adaptive Phase 2/3 study of Gemini for acute kidney injury and ongoing development efforts in kidney disease, severe burn, and post-surgical infection.
Revelation Biosciences reported 2025 results showing lower losses, a stronger balance sheet, and progress with its Gemini inflammation program. Net loss for 2025 was $8.9 million, improved from $15.0 million in 2024, as operating cash burn decreased.
Net cash used for operating activities fell to $8.3 million from $18.3 million, while cash and cash equivalents rose to $10.7 million at December 31, 2025 from $6.5 million a year earlier, helped by a May 2025 public offering and a September 2025 warrant inducement.
The company expects its cash to fund operations into the first quarter of 2027. It highlighted positive PRIME study results in late-stage chronic kidney disease, an FDA agreement on a single adaptive Phase 2/3 study of Gemini for acute kidney injury, and planned presentation of Gemini data at a major nephrology conference.
Revelation Biosciences, Inc. reported a clinical milestone by announcing positive top-line results from its PRIME phase 1b clinical study in patients with chronic kidney disease. The company described the results as “groundbreaking” in a press release issued on September 9, 2025.
Alongside the press release, Revelation Biosciences made a corporate presentation with the top-line data available to the public on its website. Both the press release and the presentation are attached as exhibits to this report, but the company states that this information will be furnished rather than filed under the Exchange Act, which means it is not subject to certain liability provisions unless specifically incorporated into other filings.
On 8 Aug 2025 Revelation Biosciences, Inc. (Nasdaq: REVB, REVBW) filed a Form 8-K to furnish, under Item 2.02, a press release announcing its financial results for the three and six months ended 30 Jun 2025. The press release itself is provided as Exhibit 99.1 but is not included in the body of the filing and is deemed “furnished,” not “filed,” under the Exchange Act, limiting liability and incorporation by reference. No revenue, EPS or balance-sheet figures appear within the 8-K text.
Aside from identifying the exhibit and reiterating the company’s security listings, the report discloses no strategic transactions, leadership changes or other material events. Consequently, the filing serves primarily as a procedural notice directing investors to the separate earnings release; market impact should be assessed only after reviewing that exhibit.
Revelation Biosciences, Inc. (Nasdaq: REVB, REVBW) released an 8-K disclosing the voting results of its 23 June 2025 Annual Meeting. A quorum of 796,075 shares (≈39% of the 2,029,796 shares outstanding) was present.
Key outcomes:
- Director election: Lakhmir Chawla was elected Class C director through 2028 (270,872 for / 33,480 against / 491,723 abstain).
- 2021 Equity Incentive Plan amendment: Share reserve will now adjust quarterly, not annually (267,539 for / 33,296 against / 495,240 abstain).
- Say-on-pay: Compensation of named executive officers approved (263,178 for / 35,009 against / 497,888 abstain).
- Say-on-pay frequency: Stockholders chose a three-year voting cycle (253,797 votes) over one-year (45,548) or two-year (2,681) options.
- Reverse stock-split authority: Board can implement one or more reverse splits within 12 months at ratios between 1-for-2 and 1-for-250 (729,206 for / 66,503 against).
- Class H Warrant share issuance: Approved to exceed the 20 % Nasdaq Exchange Cap if required (755,720 for / 37,572 against).
- Change of domicile to Nevada: Received 89 % support of votes cast but failed to reach the statutory outstanding-share threshold (268,216 for / 467,059 abstain).
- Auditor ratification: Baker Tilly US, LLP confirmed for FY-2025 (276,337 for / 20,913 against).
The meeting also featured a brief corporate update from CEO James Rolke (Exhibit 99.1), which was furnished—not filed—and therefore carries no Section 18 liability.
Investor takeaways: All operational and capital-structure proposals passed except the state-reincorporation measure. Authorization for a large (up to 1-for-250) reverse split and the ability to issue shares above the 20 % cap signal potential future dilution and efforts to maintain Nasdaq listing compliance. Quarterly “evergreen” increases to the equity plan may also raise dilution risk. No immediate financial results were disclosed.